Siegfried starts to ramp up production after cyber attack
Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says
Siegfried Group says it has started to ramp up production at its facilities after falling victim to a cyber-attack last month, although the Swiss-based CDMO warned of first-half losses in volumes and sales due to the interruption.
Siegfried said its plant in Hameln, Germany, which currently provides fill and finish services for BioNTech and Pfizer’s COVID-19 vaccine, should be fully operational again by the beginning of next week.
On the night of Friday, May 21, a malware attack on Siegfried's IT network was discovered by internal monitoring services which resulted in production being safely reduced at various locations.
The company’s network connections were interrupted and all IT systems were subsequently subjected to an in-depth investigation.
“As a result of the attack, there will be losses in volume and sales in the first half of the year with costs that continue to run during the brief interruption, but these can be made up for the whole year,” the company said in a statement.
Based on the results of advanced forensic investigations, no sensitive customer data was affected by the incident and there is no likely permanent damage to its IT infrastructure, systems and facilities, Siegfried said.
The CDMO’s two facilities in the Barcelona region of Spain, Barberà del Vallès and El Masno – which it acquired from Novartis last year -- were not affected by the incident as they run on isolated IT networks, Siegfried said.
Siegfried has facilities in Switzerland, Germany, Spain, France, Malta, the US and China and manufactures active pharmaceutical ingredients, intermediates and finished dosage forms such as tablets, capsules, sterile vials, ampoules, cartridges and ointments.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance